Trial Profile
Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV infections
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms Cell Prep
- 29 Aug 2016 Results of this and other four studies published in the Antimicrobial Agents and Chemotherapy (2016).
- 27 Jun 2016 Results of analysis of endogenous deoxynucleoside triphosphate pool (n=40) published in the Antimicrobial Agents and Chemotherapy
- 20 Nov 2013 Planned end date changed from 1 Aug 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.